In late 2004, Woo, Vieth, and colleagues from the University of Toronto presented a groundbreaking paper at the November NIH conference on vitamin D and cancer. They showed that 2,000 units of simple vitamin D3 (cholecalciferol) either reduced or prevented further increases in PSA in the majority of men with advancing prostate cancer. For the first time, a human interventional trial indicted that simple vitamin D was effective in fighting cancer.
young men with calcidiol levels below 40 nmol/L (16 ng/mL) were three times more likely to develop prostate cancer than were men with higher levels.
